Medine.co.uk

Toltramax 50 Mg/Ml Oral Suspension For Pigs

Revised: August 2012

AN: 00325/2012


Summary of Product Characteristics


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Toltramax 50 mg/ml oral suspension for pigs

(in Cyprus, Czech Republic, Denmark, France, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Romania, Spain and United Kingdom)


Scancox 50 mg/ml oral suspension for pigs

(in Poland)


Dozuril Pig 50 mg/ml oral suspension for pigs

(in Austria, Belgium, Germany and the Netherlands)


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


1 ml contains:


Active substance:


Toltrazuril

50 mg

Excipients:


Sodium benzoate (E211)

2 mg

Sodium propionate (E281)

2 mg


For a full list of excipients, see section 6.1.


3. PHARMACEUTICAL FORM


Oral suspension.

White or almost white suspension.


4. CLINICAL PARTICULARS


4.1 Target species


Pig (Piglets 3 to 5 days old).


4.2 Indications for use, specifying the target species


For the prevention of clinical signs of coccidiosis in neonatal piglets (3 to 5 days old) on farms with a confirmed history of coccidiosis caused by Isospora suis.


4.3 Contraindications


Do not use in case of hypersensitivity to the active substance or to any of the excipients.


4.4 Special warnings for each target species


As with any antiparasiticide, frequent and repeated use of antiprotozoals from the same class may lead to the development of resistance.

It is recommended to treat all animals in a pen.


Hygienic measures may reduce the risk of coccidiosis. It is therefore, recommended to improve concomitantly the hygienic conditions in the concerned facility, particularly dryness and cleanliness.


4.5 Special precautions for use


i. Special precautions for use in animals


None.


ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals


Wash any splashes from skin or eyes immediately with water.

Wash hands after use. Do not smoke, eat or drink whilst handling the product.

People with known hypersensitivity to toltrazuril should avoid contact with the veterinary medicinal product.


4.6 Adverse reactions (frequency and seriousness)


None known.


4.7 Use during pregnancy, lactation or lay


Not applicable.


4.8 Interaction with other medicinal products and other forms of interaction


None known, e.g. there is no interaction in combination with iron supplementation.


4.9 Amounts to be administered and administration route


For oral use. Individual animal treatment.

Each pig to be treated on day 3-5 of life with a single oral dose of 20 mg toltrazuril/kg body weight corresponding to 0.4 ml oral suspension per kg body weight.

The oral suspension must be shaken before use.

Due to the small volumes required to treat individual piglets, use of dosing equipment with a dose accuracy of 0.1 ml is recommended.

Treatment during an outbreak will be of limited value for the individual piglet because of damage to the small intestine having already occurred.


4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


No adverse effect has been observed in piglets after administration of a threefold overdose.


4.11 Withdrawal period(s)


Meat and offal: 77 days


5. PHARMACOLOGICAL PROPERTIES


Pharmacotherapeutic group:Antiprotozoals


ATCvet code:QP51AJ01


5.1 Pharmacodynamic properties


Toltrazuril is a triazinon derivative. It acts against coccidia of the genus Isospora. It isacting against all intracellular development stages of coccidia of the merogony (asexual multiplication) and gamogony (sexual phase). All stages are destroyed, thus the mode of action is coccidiocidal.


5.2 Pharmacokinetic particulars


After oral administration toltrazuril is slowly absorbed with a bioavailability of 70%. The maximum concentration (Cmax) of toltrazuril is of 15.1 µg/ml and is obtained after around 24 h. The main metabolite is characterised as toltrazuril sulfone. The elimination of toltrazuril is slow with a half-life elimination time around 3 days. The major route of excretion is via the faeces.


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients

Sodium benzoate (E211)

Sodium propionate (E281)

Citric acid, monohydrate

Xanthan gum

Propylene glycol

Purified water


6.2 Incompatibilities


In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.


6.3 Shelf life


Shelf-life of the veterinary medicinal product as packaged for sale: 2 years

Shelf-life after first opening the container: 3 months


6.4 Special precautions for storage


This veterinary medicinal product does not require any special storage conditions.


6.5 Nature and composition of immediate packaging


White high density polyethylene bottles containing 250 or 1000 ml of suspension with a white high density polyethylene screw cap.

Not all pack sizes may be marketed.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER


Lavet Pharmaceuticals Ltd.

Ottó u. 14.

Budapest

H-1161 Hungary


8. MARKETING AUTHORISATION NUMBER


Vm32823/4009


9. DATE OF FIRST AUTHORISATION


Date:04 April 2012


10. DATE OF REVISION OF THE TEXT


Date:August 2012


PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.


Page 5 of 5